PharmiWeb.com - Global Pharma News & Resources
25-Sep-2018

Global Gene Therapy Market 2018-2022: Market to Grow at a CAGR of 22.42% with Biogen, Gilead, Novartis, Orchard Therapeutics & Spark Therapeutics Dominating

Global Gene Therapy Market 2018-2022: Market to Grow at a CAGR of 22.42% with Biogen, Gilead, Novartis, Orchard Therapeutics & Spark Therapeutics Dominating

PR Newswire

DUBLIN, Sept. 25, 2018

DUBLIN, Sept. 25, 2018 /PRNewswire/ --

The "Global Gene Therapy Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Market to grow at a CAGR of 22.42% during the period 2018-2022.

Gene therapy is one of the most recent innovations in the pharmaceutical industry for the treatment of serious, life-threatening diseases, typically in the areas of oncology and cardiovascular. It is the usage of modified gene injected into the patient's body primarily through virus as a vector. This transmitted gene reaches the intended site to kill or treat the infected cell, thus curing the disease.

One trend affecting this market is the growing research in gene therapy for CVDs and orphan diseases. The increasing prevalence of CVDs and the urgency to treat the diseases in less time is leading the major companies to move towards more effective therapies, such as gene therapy.

According to the report, one driver influencing this market is the entry of novel molecules during the forecast period. Presently, gene therapy is one of the most advanced treatment methods in the pharmaceutical industry and there is a strong pipeline for the development of gene therapy in the forecast period.

Further, the report states that one challenge affecting this market is the high treatment costs. The competition between standard reference drug and generic drugs is intense as generics have the same therapeutic activity as the reference drug.

Key vendors



  • Biogen
  • Gilead
  • Novartis
  • Orchard Therapeutics
  • Spark Therapeutics

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

PART 06: FIVE FORCES ANALYSIS

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022


PART 07: MARKET SEGMENTATION BY THERAPY AREA

  • Segmentation by therapy area
  • Comparison by therapy area
  • Oncology
  • CNS
  • Ophthalmology
  • Rare diseases
  • Others
  • Market opportunity by therapy area

PART 08: PIPELINE

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES


PART 13: MARKET TRENDS

  • Growing research in gene therapy for CVDs and orphan diseases
  • Growing strategic alliances
  • Increasing government initiatives

PART 14: VENDOR LANDSCAPE

  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors

For more information about this report visit

https://www.researchandmarkets.com/research/nw3lc4/global_gene?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-gene-therapy-market-2018-2022-market-to-grow-at-a-cagr-of-22-42-with-biogen-gilead-novartis-orchard-therapeutics--spark-therapeutics-dominating-300718701.html

SOURCE Research and Markets

Editor Details

Last Updated: 25-Sep-2018